The Serum Angiotensin Converting Enzyme and Lysozyme Levels in Patients Non-infectious and Infectious Uveitis

Overview

This study evaluates the significance of differences in serum angiotensin converting enzyme and lysozyme levels of patients with ocular involvement of other autoimmune inflammatory and infectious diseases.

Full Title of Study: “Non-infectious and Infectious Uveitis Diagnosis”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Diagnostic
    • Masking: None (Open Label)
  • Study Primary Completion Date: February 2016

Detailed Description

Increased serum levels of angiotensin converting enzyme and lysozyme are considered as inflammatory markers for diagnosis of sarcoidosis which is an autoimmune inflammatory disease. Sarcoidosis, ankylosing spondylitis and Behcet's disease are the most common autoimmune inflammatory diseases involving the eye. Elevated serum angiotensin converting enzyme levels have also been reported in tuberculosis. Syphilis and tuberculosis are the most common infectious diseases involving the eye.

Interventions

  • Other: spectrophotometric assay
    • measurement of enzyme activity in the serum
  • Other: radial immunodiffusion
    • measurement of the precipitated ring diameters showing enzyme activity in the serum

Arms, Groups and Cohorts

  • Active Comparator: serum angiotensin converting enzyme
    • spectrophotometric assay
  • Active Comparator: serum lysozyme
    • radial immunodiffusion

Clinical Trial Outcome Measures

Primary Measures

  • Analysis of serum angiotensin converting enzyme level
    • Time Frame: 1 day

Secondary Measures

  • Analysis of serum lysozyme level
    • Time Frame: 1 day

Participating in This Clinical Trial

Inclusion Criteria

  • Subjects have ocular inflammation diagnosed as sarcoidosis, ankylosing spondylitis, behcet's disease – Subjects have ocular infection diagnosed as tuberculosis and syphilis – Subjects have refractive errors only Exclusion Criteria:

  • Subjects using ACE inhibitors, systemic steroids, immunosuppressive or immunomodulatory therapies

Gender Eligibility: All

Minimum Age: 9 Years

Maximum Age: 86 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Ozlem Sahin
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Ozlem Sahin, Medical Doctor, Specialist in Ophthalmology, Uveitis and Ocular Immunology – Dünyagöz Hospital
  • Overall Official(s)
    • Ioannis Pallikaris, MD, Study Chair, DunyaGoz Hospital, Etiler, yanarsu sokak no.1 besiktaş Istanbul Turkey
  • Overall Contact(s)
    • ozlem sahin, MD, 90-537-5523064, ozlem1158@yahoo.com

Citations Reporting on Results

Birnbaum AD, Oh FS, Chakrabarti A, Tessler HH, Goldstein DA. Clinical features and diagnostic evaluation of biopsy-proven ocular sarcoidosis. Arch Ophthalmol. 2011 Apr;129(4):409-13. doi: 10.1001/archophthalmol.2011.52.

Sen DK, Sarin GS. Immunoassay of serum muramidase (lysozyme) in ocular diseases. Indian J Ophthalmol. 1987;35(5-6):103-7.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.